In a list of gene-editing companies jotted down by your average CRISPR enthusiast, MilliporeSigma likely wouldn’t appear. Sangamo, sure. The numerous commercial spinoff companies from the Broad Institute and the University of California, certainly.
But MilliporeSigma has at least one patent that it believes every company applying the technology will need to license — and some companies are already doing that.
About the Author Reprints
